---
title: "Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission | CURX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286420726.md"
description: "Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission | CURX Stock News"
datetime: "2026-05-14T04:55:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286420726.md)
  - [en](https://longbridge.com/en/news/286420726.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286420726.md)
generator: "portal-rs"
---

# Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission | CURX Stock News

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission | CURX Stock News

### Related Stocks

- [CURX.US](https://longbridge.com/en/quote/CURX.US.md)

## Related News & Research

- [Benitec Biopharma publishes FY2026 annual report](https://longbridge.com/en/news/298957362.md)
- [Does FDA Filing Acceptance Change The Bull Case For United Therapeutics Stock?](https://longbridge.com/en/news/298918522.md)
- [Scholar Rock announces FDA approval of isembyld](https://longbridge.com/en/news/298786115.md)
- [Levi & Korsinsky Reminds Beta Bionics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 3, 2026 - BBNX](https://longbridge.com/en/news/298745336.md)
- [Nasus Pharma wins FDA clearance to start NS002 anaphylaxis study](https://longbridge.com/en/news/298915474.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**